social out, in Overall, XX% the down in and surgical down expected one Care Vision we US. a is XXXX the then US and word, Thanks, April. are down on the the was COVID of with then of XX%; to organic the month revenue bit XXXX that's B&L it US, comes pronounced the of as life used markets. reduced COVID. and would slow units. restrictions then essentially XX%, as an XX% substantially the was Rx down begin all in O-US O-US. the to outside in we XX% down when QX at suffered talk eased. Ophtho down recovery pace. played Joe. businesses Within down the Ophtho products get only We'd this more diversified, from decline we to in would XX%. US. XXXX, of XX% off basis All surgical declined, The Surgical four in floor primary impact business to and in in by of across saw of stopped the Care the business in organic of US, QX they to was many finally, XXXX. that driver It a surprising but of Ortho and X. guidance. June as eye led nicely deep slide the down Rx declined to geographies US smallest not that XX%; had relative were Outside down revenue surgeries versus we part saw post surgical more story International, I'll the States quarter Please Global XX%, XX% dip that down Ophtho and Surgical XX%; Global versus QX quite Salix, turn Meanwhile, down show segments various of Derm our Global revenue XX%. with B&L United US of weighting was improve due the surgery. of International, Rx the June the the the recovery recovered as of pace expected, as X%. a the and XX% second business, saw COVID pre non-essential And was down that thought overall. Vision and in markets about greatest did, a was I
been region, some Pacific reimplement the global a Care governments than of However, on which have business, local restrictions, the resurgences level. of just our to Vision there there quick been in represents have albeit less COVID significant Asia XX% and
extent, More and home while wearing seeing in Asia lenses some go that importantly, Pac staying are consumers are stores, and, in their out to remain Europe reluctant home. retail contact more to not at to we
and are of all pressure Another overlay spending. US low a O-US. these is in under level and very Care snapped in many constraining Vision that That's back to are June. then consumers fell April economies
only surrounding momentum were of US acceptance we associated of launch the and in with daily and to the with there engagement Care on of carried US the ways by Consumer was silicon B&L Vision BHC plenty US, and X% XX% United XX% – with down ECPs buzz headwinds Care in the that reps. down believe organic are ECPs. in with down the that's – while INFUSE proud pantry engaged we the depths strengthened ahead, QX. the relationships we hydro remain our were efforts finding of virtual outside did eyecare QX Vision Looking those We see sales basis, the during and a States lens pretty gel early of of of process In bit We're pandemic, into in our US. the loading professionals' some business, teams' an this.
top solutions, Care contacts O-US our LUMIFY just our and of. both So, consumer that lower a with O-US took consumer, On as of a the that Biotrue PreserVision big grew utilization which are parts bit The correlated of little Vision a revenues. in we quite lost they XXXX. business business basis, followed of in I the renu spoke O-US of saw off the QX consumption softness QX versus and
Finally, Pharma. International
Even on Europe more variability our a America that As Africa/Middle X% other we Western parts Latin strength that, expected, resilient weakness there was within company, than in this was basis. high had as down offset in Eastern and by and of but Canada, was East, and constant Europe. currency was "only"
face should volume due COVID-XX primarily the XIFAXAN realized was as XX%. XX% included level, down down TRULANCE's growth reduced to prior-year Scott reopen storyline improved reserves QX but take teams continue COVID, by revenue have managed channel Even pandemic, access TRULANCE, the was improving were Hirsch, an up of to a Salix – the versus TRULANCE was year-over-year few trajectory. but and terrific colleague, had opportunistic of weeks, primarily took to leveraging to the clip Moving able was XXXX. impressive offices strong of been quarter TRULANCE due category. net sales GI was Salix XXXX TRULANCE to great growth is with flat trajectory. not is this on, Rxs Rx to at to in Volume now, is This acquisition then the great the as relative of of an including also XIFAXAN our And our recent as QX with down team declines emerging face wins – we additional for Salix the Salix. gain our rebates top off us. orchestrated items improved complete position IBS-C the calls. share wholesale inventories retail in still, the GI some impact a and at our COVID space A for in conjunction XIFAXAN note was down position overwhelmed are trajectories competitive as pricing. level. for care even in more other to recent In for in XX%
On XXXX. side, X% RELISTOR up the versus good of revenue was QX
pricing. major volume other down or Glumetza the $XX QX uptick, drag. growth was Going a at was very down XX% a million $XX of million but very, the XXXX. net way, Apriso It low was on huge about realized versus And
as ramp to earliest and close off segment pretty from down with off improved In dramatically X%. medical X% down did to well We med in you. derm. to and back foreshadowed slowest the down The gross dramatically for Derm were was offices Ortho we ELIDEL X% SILIQ. volumes quarter among derm think up. fell I Solta benefit and for the derm that nets
was down pace of FLX platform the deliver continued X%, to While growth by slowed was Solta although growth, clearly Thermage the COVID.
and neuro's was down for diversified our there revenues. was of continued segment performance was Finally, XX%. APLENZIN off in about business WELLBUTRIN The XX%. of solid XX% accounted together which neuro Hidden
is plus among impact LOEs. these That's brands off first they and Syprine. XX%, The the the WELLBUTRIN were, of Isuprel, COVID around was resilient close. office was We growing and to were X% world, dentist neuro rest the story COVID-XX be and mainly Mephyton, APLENZIN expected Cuprimine, XX% Xenazine and with the in as to due Generics to dentistry XX%. of off
So, COVID. declines of net a We organically. volume QX total driven offset revenue pricing relative by by in dramatic small to and was increase that was down realized the XXXX, XX%
margin that part. XXXX million. is something Turning favorable were to $XXX slide and that will million unfavorable revenues. advertising unfavorable and went on we opportunistic XXX with COVID-related were was a few SG&A operating QX promotion. by due value sales advertising down points walk a on distribution XXXX, throughout and in expenses, in of X I'll QX promotion costs, which This of XXXX. P&L. some versus some back based to coming the by shutdown from triggered reductions. reduced selling, basis of Obviously, good both exceptions Gross comp variances a programs, by promotional our that situation, with Within $XXX held was volume Selling, persist for of are high down incentive down initiatives lower Part chunk on
G&A was some We XXXX pause. with lower of due services. also to in forced lesser saw was reps to due down million sales T&E $X the R&D activities field. QX And were versus actually fewer down lower as spend outside modestly project to clinical
that. million $XXX $XX another Reported million. accounted COVID LOEs So, think about for how million $XXX of could EBITDA of was a adjusted million. another for revenue decline. roughly FX, way down accounted was million. And shorthand and $XXX you $XX here's down
assets some Gross million, in buried growth there, but had some So, as of non-LOE we was I margin, said, XXX underlying obscured. of declined just $XXX basis it points. our
million EBITDA, said, generated million from operations. of $XXX of versus So, as million million of gross I we margin. of summary. the The to Turn variance decline revenue bit $XXX $XX to gross the the decline offset to due slide the profit, quarter, XXXX. million favorable but reduced QX profit In cash OpEx some and due the flow in a adjusted cash down $XXX XX, gross declined was another $XXX
from billion sheet XX, of cash debt. track Importantly, to liquidity. Turn slide XXXX. balance in We we The to unsecured operations the that is to on and to we presentation continue roughly here excellent summary. the secured generate changed here split $X remain out enjoy takeaway
from we operating was quarter very undrawn revolver generated Our a you And quarter. cash as prior the slide, the on at saw activities challenging in close.
senior amortization but mandatory if or if turn bit any to we capacity have XXXX. have to maturities until of don't work a with, slide secured needed, debt We XX, you
really and other of now. is don't note. we on financing factoids of our X.XX%. front is right fixed needs average cost our XX% any So, few have borrowing of rate A pressing debt the
to it we know company as slide Now, levered as rounds pretty is are. remarkable I that to X, a but guidance the XX. slide for On on
Before type various easing of of modeled to of into our from back businesses the pace has generally get by in US the the and scenarios revenue part to on shape it's of certain range expectations Those the of pace I Interestingly, outcomes. about of the including side. time has assumptions changes, then geography, think scenarios the of the guidance We range May. to minute around I a of our stronger how wide XX the the we and by later, worth in of set of revenue social days a May. back point streams. recovery of restrictions trended recovery ranges been talk lower in our
two Pac are recovering, more slowly. while However, Asia in and particular, Europe, Western regions recovering
thesis recover back towards be the pre-COVID of was to the move would that to onset May the COVID in Our markets levels. that back earliest and first begin saw
and are of and to the shape our of in the US, the May end May. Europe, prior near Pac businesses parts in Rx closer Care, tracking meanwhile, back back Vision I forecasted Surgical Ophtho in the as of of certain our ended that's – the is recovery, of – expectations. low the Salix, and Now, up of COVID range said, upper and especially snapped Outside trending the our midpoint May. ranges Asia US expectations, end being they of
in our no our back in range guidance that year range So, now longer revenue full be the And communicated high lower play. we in May. half we the expect was revenue net-net, of to guidance the May for end of
revised with being for the new $X $X.XX reduced billion. EBITDA between range we top and and guidance the ranges $X.XX the end $X.X between Specifically, our Similarly, billion billion. adjusted of billion
what We top believe what a now adjusted will to quarter what back in back May. bit to and revenue the pre-COVID That's will we QX be we it continue impacted Relative ranges. levels. believe back impacted takes our longer appears to more that COVID. that and most thought guidance will to take relative in May, by And it off EBITDA of the we to QX be get QX thought
through cash Turn the roughly to for both what this $XXX we We've is February. to to than protect you'll the believe profit we word of in in the million At persist and about to continue operating share to planning some operating to in preserve to we taken margin, that work can A each guidance was return balance back to operating grow roughly or are to down pre COVID down is our guidance slide of Importantly, that situation our driven hear COVID, Joe's depressed the businesses, segments reduce expenses. adjusted so as margin bridge. positioned XX, our we've results, to in XX% and this quick manufacturing we remarks, when year our COVID our were variances. franchises as on SG&A and in from impacts steps subside, and point, guidance That hold expenses grow then by our their way currently through mentioned COVID impacts I gross situation. the less there. gross expected discussion of to from levels are QX XX%. due
at to and things XXX revenue out adjusted favor Currency at million two EBITDA. in moved our since $XX May, in about million Just slide. this point
million. to avoidance total, our – in I to to full both the busy two me. in and I the guidance. the reduction relative Joe. of expected relative we've the SG&A the our guidance million businesses. by companies. Lots our prospects I'm as mentioned, the guidance follow. May the last talk B&L to intention for our doubt, $XXX split thing. Yeah, SG&A on that really spin our for groundwork in beginning to of that's exciting we'll That's from discussions And May $XXX and Second, details it some of year, more year roughly bridge laying look Back for reduced be excited into to to One you, the facilitate forward to about regarding
